Key Highlights

  • The stock ended November 17, 2026 down 16.55%, roughly 16.6% lower, at about USD 13.92 a share.
  • Third-quarter net Revenue for YARTEMLEA amounted to USD 35.9 million, under the USD 37.3 million analyst estimate, yet it grew 26% on the previous quarter.
  • A USD 62.0 million non-cash hit linked to 2029 convertible notes drove the GAAP net loss to USD 57.4 million.
  • Cash and short-term investments stood at USD 95.3 million as of late September.

Sequential Growth Falls Short of Expectations

Omeros (NASDAQ:OMER) has staked its recent momentum on narsoplimab, sold as YARTEMLEA, its first product to reach commercial shelves. The US approval addresses transplant-associated thrombotic microangiopathy, a scarce and often deadly complication arising after stem cell transplants. Across the last twelve months this launch has been the chief influence on the shares. Gross product revenue in the third quarter jumped roughly 30% against the second quarter, reaching USD 41.8 million, while net revenue increased 26%, moving from USD 28.5 million up to USD 35.9 million. The gap between gross and net widened to 14.0% from 11.5%, reflecting larger rebates and discounts taken out of list-price sales. Growth of that kind over a single quarter is encouraging for a rare-disease launch, although the market had been pencilling in a bigger figure. The roughly USD 1.4 million shortfall against consensus is minor in cash terms, but for a company that depends on one product, the direction of travel counts for more than any single quarter. Physician education and hospital formulary decisions often make early sales lumpy.

Non-Cash Accounting Behind the Headline Loss

A GAAP net loss of USD 57.4 million, which works out to USD 0.79 a share, looks severe at first glance, though much of it is non-cash. Omeros booked a USD 62.0 million loss on a derivative tied to its 2029 convertible notes, an instrument that gains value as the share price climbs. Once those items are excluded, adjusted Net Income came to USD 4.7 million, or USD 0.06 per share, against USD 1.8 million in the prior quarter. Operating Cash Flow reached USD 13.3 million, a milestone indicating that YARTEMLEA now covers running costs. The company also bought back part of its 2029 notes, leaving roughly USD 40.3 million of principal. A new Medicare technology add-on payment of up to USD 287,079 per eligible inpatient case, effective October 1, should make hospitals more willing to use the drug. Positive operating cash also reduces the likelihood of a near-term Equity raise, a concern that had troubled investors earlier in the launch.

Europe Setback and Coming Catalysts

The pressure was not confined to one market. In October a European advisory committee gave a negative opinion on the Marketing application after a second review, which limits near-term possibilities across the region. Adoption also depends on how rapidly transplant centres build the drug into standard protocols, since uptake in rare diseases tends to be concentrated in a few high-volume hospitals. The wider backdrop offered no help: the S&P 500 lost 1.03%, and healthcare stocks slipped after a proposal to broaden Medicare Advantage audits. From here attention centres on fourth-quarter sales, any reimbursement gains and pipeline progress, including complement inhibitors for other diseases. The shares had run hard before the report, which invited profit-taking on any setback, and a fall of more than 16% over a modest revenue gap shows how much hope was already baked in. Volatility is likely to persist until two or three quarters of sales clarify the trend.

Where Things Stand

Omeros (NASDAQ:OMER) is lifting YARTEMLEA revenue and has moved into positive operating cash generation, yet a thin revenue miss plus a European rebuff prompted a heavy sell-off on November 17. Fourth-quarter figures will indicate whether the launch keeps its pace. Cash inflows and lower borrowing leave management room to prove its case.